MOVE

Movano Inc. (MOVE) Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Movano Inc. (dba Movano Health) is an early-stage technology company developing a platform for medical-grade health data, primarily through its commercial product, the Evie Ring. The company is also developing a proprietary System-on-a-Chip (SoC) for non-invasive glucose and cuffless blood pressure monitoring. Movano is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Note: Revenue for Q2 2024 was $0 due to customer refunds and returns offsetting recognized revenue. YTD 2024 revenue of $0.9 million reflects initial product transfers in Q1.

Material Changes vs. Prior Period

• Capital Raise: In April 2024, the company completed a private placement raising approximately $24.1 million in gross proceeds (net of ~$1.4 million fees) via the sale of 45.3 million units (common stock/pre-funded warrants and warrants). This significantly increased cash reserves from $6.1 million at year-end 2023 to $16.9 million.
• Expense Reduction: Operating expenses decreased by 11% year-over-year for the six-month period. Research and Development (R&D) expenses dropped 28% to $5.8 million, and Sales, General, and Administrative (SG&A) expenses dropped 14% to $5.6 million, driven by lower headcount and professional fees.
• Revenue Recognition: While the company began transferring control of Evie Ring products in Q1 2024, Q2 revenue was fully offset by returns. Consequently, Q2 revenue is reported as $0, whereas YTD revenue stands at $0.9 million.
• Share Count: Outstanding common shares increased from 55.8 million (Dec 31, 2023) to 98.9 million (June 30, 2024) due to the April 2024 private placement and At-The-Market (ATM) issuances.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. The company expects to incur additional losses and requires further financing to fund operations, R&D, and commercialization.
• Product Development: The company withdrew a 2023 FDA 510(k) submission for the EvieMED Ring and re-submitted in April 2024 following a second pivotal hypoxia trial. They are also conducting clinical trials for their SoC technology for non-invasive glucose and blood pressure monitoring.
• Liquidity: Cash on hand ($16.9 million) is not expected to be sufficient to fund operations for the next 12 months. The company relies on equity offerings (including an ATM program with ~$43.9 million remaining capacity) or strategic alliances for future funding.
• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to ineffective design and operation of financial close and reporting controls, which rendered disclosure controls ineffective as of June 30, 2024.
• Subsequent Event: On July 9, 2024, the company increased its authorized common stock from 150 million to 500 million shares.

Investor Verification Checklist

• Runway Analysis: Verify the burn rate against the $16.9 million cash balance to confirm the timeline for the next required capital raise.
• Revenue Quality: Investigate the high return/refund rate that offset Q2 revenue, as this impacts gross margin and future revenue recognition reliability.
• FDA Status: Monitor the status of the re-submitted 510(k) application for EvieMED, as regulatory clearance is critical for the medical device revenue model.
• Dilution Risk: Assess the impact of the 45.3 million warrants issued in April 2024 (exercise price ~$0.41) and the remaining ATM capacity on future shareholder dilution.
• Internal Control Remediation: Review progress on remediation of the material weakness in financial reporting controls to ensure future financial statement reliability.